Form 4: Karyopharm Therapeutics Director Acquires 69,000 Stock Options
SEC Form 4 Filing
Barry E. Greene, a director at Karyopharm Therapeutics Inc., acquired 69,000 nonstatutory stock options on May 29, 2024.
Summary
- On May 29, 2024, Barry E. Greene, a director of Karyopharm Therapeutics Inc., acquired 69,000 nonstatutory stock options.
- The exercise price of these options is $0.96.
- The options vest 100% on May 29, 2025.
- The options expire on May 28, 2034.
- Following the transaction, Greene directly owns 69,000 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of a stock option grant to a director. While insider ownership can be a positive signal, this is a standard transaction.
Positives
- A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership by a company insider. Such filings are common and provide transparency into the transactions of company directors and officers.
Stakeholder Impact
- The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment, as it aligns the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 05/29/2024 | Date of transaction and acquisition of stock options. |
| 05/29/2025 | Date when the stock options vest 100%. |
| 05/28/2034 | Expiration date of the stock options. |
| 05/30/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.